YUE WEI to Humans
This is a "connection" page, showing publications YUE WEI has written about Humans.
Connection Strength
0.182
-
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol. 2022 Nov; 115:44-53.
Score: 0.017
-
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. 2022 08; 36(8):2097-2107.
Score: 0.017
-
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5.
Score: 0.010
-
Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-?B activation and enhances erythroid differentiation arrest. PLoS One. 2014; 9(4):e93404.
Score: 0.010
-
Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013 Dec; 65:750-764.
Score: 0.009
-
Toll-like receptor alterations in myelodysplastic syndrome. Leukemia. 2013 Sep; 27(9):1832-40.
Score: 0.009
-
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013 Nov; 27(11):2177-86.
Score: 0.009
-
Histone methylation in myelodysplastic syndromes. Epigenomics. 2011 Apr; 3(2):193-205.
Score: 0.008
-
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy. 2010 Oct; 6(7):976-8.
Score: 0.008
-
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res. 2010 Aug 01; 16(15):3923-32.
Score: 0.007
-
The cyclin E/Cdk2 substrate and Cajal body component p220(NPAT) activates histone transcription through a novel LisH-like domain. Mol Cell Biol. 2003 May; 23(10):3669-80.
Score: 0.004
-
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
Score: 0.004
-
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
Score: 0.004
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.004
-
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res. 2021 02; 101:106511.
Score: 0.004
-
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499.
Score: 0.004
-
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020 03; 34(3):872-881.
Score: 0.004
-
Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res. 2017 08; 59:85-92.
Score: 0.003
-
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S67-73.
Score: 0.003
-
Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016 May; 44:1-7.
Score: 0.003
-
Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma. 2015; 56(12):3426-33.
Score: 0.003
-
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
Score: 0.003
-
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. Br J Haematol. 2015 May; 169(3):344-51.
Score: 0.003
-
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
Score: 0.002
-
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
Score: 0.002
-
Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One. 2013; 8(8):e71120.
Score: 0.002
-
Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 2013 Sep; 88(9):784-9.
Score: 0.002
-
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.
Score: 0.002
-
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
Score: 0.002
-
Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood. 2013 May 09; 121(19):4009-11.
Score: 0.002
-
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One. 2013; 8(4):e61807.
Score: 0.002
-
Exome capture sequencing identifies a novel mutation in BBS4. Mol Vis. 2011; 17:3529-40.
Score: 0.002
-
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 2011 Feb; 86(2):237-8.
Score: 0.002
-
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16; 5(6):499-508.
Score: 0.002
-
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate. Blood. 2010 Oct 14; 116(15):2732-41.
Score: 0.002
-
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leuk Res. 2010 Feb; 34(2):221-8.
Score: 0.002
-
Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia. 2008 Aug; 22(8):1529-38.
Score: 0.002
-
HiNF-P directly links the cyclin E/CDK2/p220NPAT pathway to histone H4 gene regulation at the G1/S phase cell cycle transition. Mol Cell Biol. 2005 Jul; 25(14):6140-53.
Score: 0.001
-
The cyclin E/Cdk2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol Cell Biol. 2003 Dec; 23(23):8586-600.
Score: 0.001
-
Identification of HiNF-P, a key activator of cell cycle-controlled histone H4 genes at the onset of S phase. Mol Cell Biol. 2003 Nov; 23(22):8110-23.
Score: 0.001
-
BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature. 2003 Sep 18; 425(6955):316-21.
Score: 0.001
-
Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 2000 Sep 15; 14(18):2298-313.
Score: 0.001